Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;20(1):8-15.
doi: 10.1111/papr.12818. Epub 2019 Oct 21.

Long-term Outcome and Adverse Events of Intrathecal Opioid Therapy for Nonmalignant Pain Syndrome

Björn Sommer  1   2 , Nikolaos Karageorgos  1 , Mustafa AlSharif  1 , Henning Stubbe  3 , Franz-Josef Hans  1
Affiliations

Long-term Outcome and Adverse Events of Intrathecal Opioid Therapy for Nonmalignant Pain Syndrome

Björn Sommer et al. Pain Pract. 2020 Jan.

Abstract

Objective: Intrathecal (IT) opioid pumps are one therapeutic cornerstone of refractory nonmalignant pain syndromes. The aim of this study was to evaluate the efficacy of and surgical and pharmacological complications of IT pumps beyond a time span of 10 years.

Methods: In this retrospective single-center cohort study, 27 patients (14 female, 13 male, age 64.0 ± 8.9 [median, 1 SD] years) were identified. Pain intensity using the numeric rating scale (NRS), pain and IT pump characteristics, and complications were analyzed. The German Pain Questionnaire was used to investigate the physical and mental health status.

Results: Overall time of IT therapy from first implantation to last follow-up was 20.4 ± 6.0 years. Time to implantation of the second pump (n = 18) was 10.0 ± 5.3 years, and between the second and third pump (n = 6) 6.5 ± 2.7 years; 2 patients received their fourth pump 6 years later. The NRS score was 9.0 ± 0.9 before implantation, 7.0 ± 1.8 1 year after implantation, and 4.0 ± 2.3 at the last follow-up. IT drug dose remained stable after 3 years. Opioid intoxications occurred in 3 patients (10%). One patient (3%) underwent revision surgery due to a catheter infection. Drug side effects occurred in 4 patients (14%). Our patient group had pain-related restrictions in physical activities with menial impact regarding mental and emotional stress.

Conclusion: Even after a time span of over 15 years and several exchanges of pump systems, pain intensity was still reduced. After 3 years, IT drug dose remained unchanged with low side-effect and complication rates.

Keywords: complications; implantable drug delivery; intrathecal morphine; long-term outcome; pain scores.

PubMed Disclaimer

References

    1. Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56:516-520.
    1. Kumar K, Rizvi S, Bishop S. Cost effectiveness of intrathecal drug therapy in management of nonmalignant pain. Clin J Pain. 2013;29:138-145.
    1. Duarte RV, Lambe T, Raphael JH, Eldabe S, Andronis L. Intrathecal drug delivery systems for the management of chronic noncancer pain: a systematic review on economic evaluations. Pain Pract. 2018;18:666-686.
    1. Groenewald CB, Palermo TM. The price of pain: the economics of chronic adolescent pain. Pain Manag. 2015;5:61-64.
    1. Duarte RV, Raphael JH, Sparkes E, Southall JL, LeMarchand K, Ashford RL. Long-term intrathecal drug administration for chronic nonmalignant pain. J Neurosurg Anesthesiol. 2012;24:63-70.

Substances

LinkOut - more resources